A Comprehensive Review of Designing and Synthetic Aspects of Pyrazolopyrimidine Derivatives as Anticancer Agents

Pyrazolopyrimidines are a fascinating class of heterocyclic compounds that have attracted considerable interest for their potential in cancer therapy. Their unique scaffold allows flexible chemical modifications, enabling them to interact with various cancer-related proteins- especially kinases that regulate tumor growth and survival.

This review highlights recent advancements in the design, synthesis, and biological evaluation of pyrazolopyrimidine derivatives, emphasizing their role as targeted anticancer agents.

We analyzed recent literature (2000-2025) covering synthetic strategies, anticancer targets, in silico studies on anticancer targets and their mechanisms, off-target mechanisms, and patent information. The review also focuses on how these methods guide the optimization of Structure- Activity Relationships (SAR) and improve compound efficacy.

Numerous pyrazolopyrimidine derivatives demonstrated significant anticancer activity across various cell lines, including breast, liver, colorectal, and haematological malignancies. Mechanistic investigations revealed that these derivatives target key oncogenic pathways, such as CDKs, EGFR (including resistant mutants), mTOR, TOPO II, and HDACs. They exert anticancer effects by inducing apoptosis, arresting cells at S or M phases, and downregulating proliferation markers. Several studies also report favourable selectivity for cancer cells, improved bioavailability, and metabolic stability, supporting their drug-like properties.

When rational drug-design approaches such as molecular docking, DFT calculations, and ADME profiling are considered together, pyrazolopyrimidine derivatives stand out as particularly promising multi-target anticancer agents. Across multiple studies, several compounds display anticancer activities that are comparable to, and occasionally stronger than, those of standard chemotherapeutic drugs like doxorubicin and cisplatin. Importantly, these effects are often accompanied by better selectivity toward cancer cells, suggesting a potential safety advantage. A noteworthy strength of this scaffold is its ability to target clinically relevant resistance pathways, including P-glycoprotein-mediated drug efflux and EGFR T790M mutations, which frequently limit the effectiveness of current therapies. While their ATP-mimetic binding mode allows interaction with a broad range of kinases, it also underscores the need for careful optimization to improve target selectivity and reduce unintended interactions. Although the available in vitro results and early in vivo studies indicate meaningful tumor growth inhibition with minimal toxicity, further work is clearly needed. Detailed pharmacokinetic, pharmacodynamic, and long-term toxicological studies will be essential before these compounds can be realistically advanced toward clinical application.

Pyrazolopyrimidines represent a versatile and promising class with strong in vivo efficacy, selectivity, and a favorable toxicity profile. Their ability to engage multiple targets and overcome resistance highlights their potential for integration in oncology. However, further systematic in vivo and clinical studies are essential to translate their potential into therapeutic success.